Cellectar Biosciences Balance Sheet Health
Financial Health criteria checks 4/6
Cellectar Biosciences has a total shareholder equity of $13.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $29.4M and $15.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$25.87m |
| Equity | US$13.76m |
| Total liabilities | US$15.62m |
| Total assets | US$29.38m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NV4's short term assets ($27.9M) exceed its short term liabilities ($15.2M).
Long Term Liabilities: NV4's short term assets ($27.9M) exceed its long term liabilities ($453.5K).
Debt to Equity History and Analysis
Debt Level: NV4 is debt free.
Reducing Debt: NV4 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NV4 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: NV4 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 23.9% each year